Organigram Global Inc. income statement

In fiscal 2025, Organigram Global Inc. reported revenue of $185m, up 57.8% on the year before, operating income of −$10.9m (a -5.9% margin) and net income of −$17.7m, or −$0.14 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Organigram Global Inc.: income statement, annual
Fiscal year	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Aug 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Revenue	10	61	65	62	115	120	117	185
Cost of revenue	4	32	78	82	94	101	82	125
Gross profit	40	37	−42	−22	25	28	35	65
Research and development	0	0	1	3	5	10	8	8
Operating income	29	4	−108	−72	−34	−195	−26	−11
Interest expense	—	—	0	0	0	0	0	0
Income before tax	22	−4	−109	−103	−11	−187	−33	−28
Income tax	4	3	−8	0	−0	−3	0	−10
Net income	16	−7	−101	−103	−11	−185	−33	−18
Diluted EPS	$0.51	−$0.21	−$2.35	−$1.61	−$0.14	−$2.27	−$0.35	−$0.14
Diluted shares (average)	32m	38m	45m	64m	77m	81m	95m	128m
EBITDA	29	5	−107	−70	−30	−191	−23	−5

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BTMD vs OGI KMDA vs OGI CRON vs OGI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Organigram Global Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organigram Global Inc.